Literature DB >> 23010473

Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas.

Jenny Welander1, Catharina Larsson, Martin Bäckdahl, Niyaz Hareni, Tobias Sivlér, Michael Brauckhoff, Peter Söderkvist, Oliver Gimm.   

Abstract

Pheochromocytomas are neuroendocrine tumors of the adrenal medulla which can occur either sporadically or in the context of hereditary tumor syndromes. Whereas the genetic background of hereditary pheochromocytomas is becoming rather well-defined, very little is known about the more common sporadic form of the disease which constitutes ∼70% of all cases. In this study, we elucidate some of the molecular mechanisms behind sporadic pheochromocytoma by performing a comprehensive analysis of copy number alterations, gene expression, promoter methylation and somatic mutations in the genes RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1Bβ, TMEM127 and MAX, which have been associated with hereditary pheochromocytoma or paraganglioma. Our genomic and genetic analyses of 42 sporadic pheochromocytomas reveal that a large proportion (83%) has an altered copy number in at least one of the known susceptibility genes, often in association with an altered messenger RNA (mRNA) expression. Specifically, 11 sporadic tumors (26%) displayed a loss of one allele of the NF1 gene, which significantly correlated with a reduced NF1 mRNA expression. Subsequent sequencing of NF1 mRNA, followed by confirmation in the corresponding genomic DNA (gDNA), revealed somatic truncating mutations in 10 of the 11 tumors with NF1 loss. Our results thus suggest that the NF1 gene constitutes the most frequent (24%) target of somatic mutations so far known in sporadic pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010473     DOI: 10.1093/hmg/dds402

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

3.  Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.

Authors:  Joakim Crona; Angela Lamarca; Suman Ghosal; Staffan Welin; Britt Skogseid; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-05       Impact factor: 5.678

Review 4.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 5.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

6.  Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma.

Authors:  Adam Stenman; Fredrika Svahn; Jenny Welander; Boel Gustavson; Peter Söderkvist; Oliver Gimm; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 7.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

8.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 9.  Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.

Authors:  Ales Vicha; Zdenek Musil; Karel Pacak
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-06       Impact factor: 3.243

Review 10.  Hyperplasia in glands with hormone excess.

Authors:  Stephen J Marx
Journal:  Endocr Relat Cancer       Date:  2015-09-25       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.